APO Research
Talk to an analyst

APO RESEARCH · REPORT

C-MET & HGF Inhibitors

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Selected research

Industry Research

C-MET & HGF Inhibitors Industry Research Report 2026

27 December 2025143 pages

Choose your research edition.

Industry ResearchC-MET & HGF Inhibitors Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal C-MET & HGF Inhibitors Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal C-MET & HGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C-MET & HGF Inhibitors Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal C-MET & HGF Inhibitors Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.

C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.

Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.

Report Scope

This report quantifies the global C-MET & HGF Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

C-MET & HGF Inhibitors Market by Company

Exelixis

Ipsen

Pfizer

Novartis

Takeda

Merck KGaA

Merck

Daiichi Sankyo

GSK

Bristol-Myers Squibb(BMS)

Roche

AVEO Pharmaceuticals

Amgen

AstraZeneca

Mirati Therapeutics

Eli Lilly

Johnson & Johnson

Eisai

Hutchison MediPharma

Kringle Pharmaceuticals

C-MET & HGF Inhibitors Segment by Type

Cabozantinib

Crizotinib

Others

C-MET & HGF Inhibitors Segment by Application

Hospital

Drug Store

C-MET & HGF Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-MET & HGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C-MET & HGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-MET & HGF Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of C-MET & HGF Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of C-MET & HGF Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global C-MET & HGF Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global C-MET & HGF Inhibitors Sales (K Units) of Manufacturers (2021-2026) Table 7. Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 8. Global C-MET & HGF Inhibitors Revenue of Manufacturers (2021-2026) Table 9. Global C-MET & HGF Inhibitors Revenue Share by Manufacturers (2021-2026) Table 10. Global Market C-MET & HGF Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global C-MET & HGF Inhibitors Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of C-MET & HGF Inhibitors, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of C-MET & HGF Inhibitors, Product Type & Application Table 14. Global C-MET & HGF Inhibitors Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global C-MET & HGF Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Exelixis Company Information Table 19. Exelixis Business Overview Table 20. Exelixis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Exelixis C-MET & HGF Inhibitors Product Portfolio Table 22. Exelixis Recent Developments Table 23. Ipsen Company Information Table 24. Ipsen Business Overview Table 25. Ipsen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Ipsen C-MET & HGF Inhibitors Product Portfolio Table 27. Ipsen Recent Developments Table 28. Pfizer Company Information Table 29. Pfizer Business Overview Table 30. Pfizer C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Pfizer C-MET & HGF Inhibitors Product Portfolio Table 32. Pfizer Recent Developments Table 33. Novartis Company Information Table 34. Novartis Business Overview Table 35. Novartis C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Novartis C-MET & HGF Inhibitors Product Portfolio Table 37. Novartis Recent Developments Table 38. Takeda Company Information Table 39. Takeda Business Overview Table 40. Takeda C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Takeda C-MET & HGF Inhibitors Product Portfolio Table 42. Takeda Recent Developments Table 43. Merck KGaA Company Information Table 44. Merck KGaA Business Overview Table 45. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Merck KGaA C-MET & HGF Inhibitors Product Portfolio Table 47. Merck KGaA Recent Developments Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Merck C-MET & HGF Inhibitors Product Portfolio Table 52. Merck Recent Developments Table 53. Daiichi Sankyo Company Information Table 54. Daiichi Sankyo Business Overview Table 55. Daiichi Sankyo C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio Table 57. Daiichi Sankyo Recent Developments Table 58. GSK Company Information Table 59. GSK Business Overview Table 60. GSK C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. GSK C-MET & HGF Inhibitors Product Portfolio Table 62. GSK Recent Developments Table 63. Bristol-Myers Squibb(BMS) Company Information Table 64. Bristol-Myers Squibb(BMS) Business Overview Table 65. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio Table 67. Bristol-Myers Squibb(BMS) Recent Developments Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Roche C-MET & HGF Inhibitors Product Portfolio Table 72. Roche Recent Developments Table 73. AVEO Pharmaceuticals Company Information Table 74. AVEO Pharmaceuticals Business Overview Table 75. AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 77. AVEO Pharmaceuticals Recent Developments Table 78. Amgen Company Information Table 79. Amgen Business Overview Table 80. Amgen C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Amgen C-MET & HGF Inhibitors Product Portfolio Table 82. Amgen Recent Developments Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. AstraZeneca C-MET & HGF Inhibitors Product Portfolio Table 87. AstraZeneca Recent Developments Table 88. Mirati Therapeutics Company Information Table 89. Mirati Therapeutics Business Overview Table 90. Mirati Therapeutics C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio Table 92. Mirati Therapeutics Recent Developments Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Eli Lilly C-MET & HGF Inhibitors Product Portfolio Table 97. Eli Lilly Recent Developments Table 98. Johnson & Johnson Company Information Table 99. Johnson & Johnson Business Overview Table 100. Johnson & Johnson C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio Table 102. Johnson & Johnson Recent Developments Table 103. Eisai Company Information Table 104. Eisai Business Overview Table 105. Eisai C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Eisai C-MET & HGF Inhibitors Product Portfolio Table 107. Eisai Recent Developments Table 108. Hutchison MediPharma Company Information Table 109. Hutchison MediPharma Business Overview Table 110. Hutchison MediPharma C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio Table 112. Hutchison MediPharma Recent Developments Table 113. Kringle Pharmaceuticals Company Information Table 114. Kringle Pharmaceuticals Business Overview Table 115. Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 117. Kringle Pharmaceuticals Recent Developments Table 118. Global C-MET & HGF Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global C-MET & HGF Inhibitors Sales by Region (2021-2026) & (K Units) Table 120. Global C-MET & HGF Inhibitors Sales Market Share by Region (2021-2026) Table 121. Global C-MET & HGF Inhibitors Sales by Region (2027-2032) & (K Units) Table 122. Global C-MET & HGF Inhibitors Sales Market Share by Region (2027-2032) Table 123. Global C-MET & HGF Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 124. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2021-2026) Table 125. Global C-MET & HGF Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 126. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2027-2032) Table 127. North America C-MET & HGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 129. North America C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 130. North America C-MET & HGF Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 131. North America C-MET & HGF Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe C-MET & HGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 134. Europe C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 135. Europe C-MET & HGF Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe C-MET & HGF Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific C-MET & HGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 139. Asia Pacific C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 140. Asia Pacific C-MET & HGF Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific C-MET & HGF Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 142. South America C-MET & HGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 144. South America C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 145. South America C-MET & HGF Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 146. South America C-MET & HGF Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa C-MET & HGF Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 150. Middle East and Africa C-MET & HGF Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa C-MET & HGF Inhibitors Revenue by Country (2027-2032) & (US$ Million) Table 152. Global C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 153. Global C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 154. Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2026) Table 155. Global C-MET & HGF Inhibitors Sales Market Share by Type (2027-2032) Table 156. Global C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 157. Global C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 158. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2026) Table 159. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2027-2032) Table 160. Global C-MET & HGF Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 161. Global C-MET & HGF Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 162. Global C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 163. Global C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 164. Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2026) Table 165. Global C-MET & HGF Inhibitors Sales Market Share by Application (2027-2032) Table 166. Global C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 167. Global C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 168. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2026) Table 169. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2027-2032) Table 170. Global C-MET & HGF Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 171. Global C-MET & HGF Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. C-MET & HGF Inhibitors Distributors List Table 175. C-MET & HGF Inhibitors Customers List Table 176. C-MET & HGF Inhibitors Industry Trends Table 177. C-MET & HGF Inhibitors Industry Drivers Table 178. C-MET & HGF Inhibitors Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. C-MET & HGF Inhibitors Product Image Figure 5. Global C-MET & HGF Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global C-MET & HGF Inhibitors Market Size (2021-2032) & (US$ Million) Figure 7. Global C-MET & HGF Inhibitors Sales (2021-2032) & (K Units) Figure 8. Global C-MET & HGF Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 9. Cabozantinib Product Image Figure 10. Crizotinib Product Image Figure 11. Others Product Image Figure 12. Hospital Product Image Figure 13. Drug Store Product Image Figure 14. Global C-MET & HGF Inhibitors Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of C-MET & HGF Inhibitors, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 C-MET & HGF Inhibitors Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global C-MET & HGF Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global C-MET & HGF Inhibitors Sales by Region in 2025 Figure 20. Global C-MET & HGF Inhibitors Revenue by Region in 2025 Figure 21. North America C-MET & HGF Inhibitors Market Size by Country in 2025 Figure 22. North America C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 23. North America C-MET & HGF Inhibitors Revenue Market Share by Country (2021-2032) Figure 24. United States C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe C-MET & HGF Inhibitors Market Size by Country in 2025 Figure 28. Europe C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 29. Europe C-MET & HGF Inhibitors Revenue Market Share by Country (2021-2032) Figure 30. Germany C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific C-MET & HGF Inhibitors Market Size by Country in 2025 Figure 41. Asia Pacific C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific C-MET & HGF Inhibitors Revenue Market Share by Country (2021-2032) Figure 43. China C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America C-MET & HGF Inhibitors Market Size by Country in 2025 Figure 52. South America C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 53. South America C-MET & HGF Inhibitors Revenue Market Share by Country (2021-2032) Figure 54. Brazil C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa C-MET & HGF Inhibitors Market Size by Country in 2025 Figure 58. Middle East and Africa C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa C-MET & HGF Inhibitors Revenue Market Share by Country (2021-2032) Figure 60. Egypt C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries C-MET & HGF Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2032) Figure 66. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2032) Figure 67. Global C-MET & HGF Inhibitors Price (US$/Unit) by Type (2021-2032) Figure 68. Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2032) Figure 69. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2032) Figure 70. Global C-MET & HGF Inhibitors Price (US$/Unit) by Application (2021-2032) Figure 71. C-MET & HGF Inhibitors Value Chain Figure 72. C-MET & HGF Inhibitors Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. C-MET & HGF Inhibitors Industry Opportunities and Challenges

Scope & coverage.

Types
  • Cabozantinib
  • Crizotinib
  • Others
Applications
  • Hospital
  • Drug Store
Companies covered
  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Merck
  • Daiichi Sankyo
  • GSK
  • Bristol-Myers Squibb(BMS)
  • Roche
  • AVEO Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Mirati Therapeutics
  • Eli Lilly
  • Johnson & Johnson
  • Eisai
  • Hutchison MediPharma
  • Kringle Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global C-MET & HGF Inhibitors Market Size (2021-2032)
  4. 2.2.2 Global C-MET & HGF Inhibitors Sales (2021-2032)
  5. 2.2.3 Global C-MET & HGF Inhibitors Market Average Price (2021-2032)
  6. 2.3 C-MET & HGF Inhibitors by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Cabozantinib
  9. 2.3.3 Crizotinib
  10. 2.3.4 Others
  11. 2.4 C-MET & HGF Inhibitors by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital
  14. 2.4.3 Drug Store
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global C-MET & HGF Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global C-MET & HGF Inhibitors Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global C-MET & HGF Inhibitors Revenue of Manufacturers (2021-2026)
  4. 3.4 Global C-MET & HGF Inhibitors Average Price by Manufacturers (2021-2026)
  5. 3.5 Global C-MET & HGF Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of C-MET & HGF Inhibitors, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of C-MET & HGF Inhibitors, Product Type & Application
  8. 3.8 Global Manufacturers of C-MET & HGF Inhibitors, Established Date
  9. 3.9 Global C-MET & HGF Inhibitors Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Exelixis
  2. 4.1.1 Exelixis Company Information
  3. 4.1.2 Exelixis Business Overview
  4. 4.1.3 Exelixis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio
  6. 4.1.5 Exelixis Recent Developments
  7. 4.2 Ipsen
  8. 4.2.1 Ipsen Company Information
  9. 4.2.2 Ipsen Business Overview
  10. 4.2.3 Ipsen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio
  12. 4.2.5 Ipsen Recent Developments
  13. 4.3 Pfizer
  14. 4.3.1 Pfizer Company Information
  15. 4.3.2 Pfizer Business Overview
  16. 4.3.3 Pfizer C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio
  18. 4.3.5 Pfizer Recent Developments
  19. 4.4 Novartis
  20. 4.4.1 Novartis Company Information
  21. 4.4.2 Novartis Business Overview
  22. 4.4.3 Novartis C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio
  24. 4.4.5 Novartis Recent Developments
  25. 4.5 Takeda
  26. 4.5.1 Takeda Company Information
  27. 4.5.2 Takeda Business Overview
  28. 4.5.3 Takeda C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio
  30. 4.5.5 Takeda Recent Developments
  31. 4.6 Merck KGaA
  32. 4.6.1 Merck KGaA Company Information
  33. 4.6.2 Merck KGaA Business Overview
  34. 4.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio
  36. 4.6.5 Merck KGaA Recent Developments
  37. 4.7 Merck
  38. 4.7.1 Merck Company Information
  39. 4.7.2 Merck Business Overview
  40. 4.7.3 Merck C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Merck C-MET & HGF Inhibitors Product Portfolio
  42. 4.7.5 Merck Recent Developments
  43. 4.8 Daiichi Sankyo
  44. 4.8.1 Daiichi Sankyo Company Information
  45. 4.8.2 Daiichi Sankyo Business Overview
  46. 4.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio
  48. 4.8.5 Daiichi Sankyo Recent Developments
  49. 4.9 GSK
  50. 4.9.1 GSK Company Information
  51. 4.9.2 GSK Business Overview
  52. 4.9.3 GSK C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 GSK C-MET & HGF Inhibitors Product Portfolio
  54. 4.9.5 GSK Recent Developments
  55. 4.10 Bristol-Myers Squibb(BMS)
  56. 4.10.1 Bristol-Myers Squibb(BMS) Company Information
  57. 4.10.2 Bristol-Myers Squibb(BMS) Business Overview
  58. 4.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio
  60. 4.10.5 Bristol-Myers Squibb(BMS) Recent Developments
  61. 4.11 Roche
  62. 4.11.1 Roche Company Information
  63. 4.11.2 Roche Business Overview
  64. 4.11.3 Roche C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Roche C-MET & HGF Inhibitors Product Portfolio
  66. 4.11.5 Roche Recent Developments
  67. 4.12 AVEO Pharmaceuticals
  68. 4.12.1 AVEO Pharmaceuticals Company Information
  69. 4.12.2 AVEO Pharmaceuticals Business Overview
  70. 4.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  72. 4.12.5 AVEO Pharmaceuticals Recent Developments
  73. 4.13 Amgen
  74. 4.13.1 Amgen Company Information
  75. 4.13.2 Amgen Business Overview
  76. 4.13.3 Amgen C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Amgen C-MET & HGF Inhibitors Product Portfolio
  78. 4.13.5 Amgen Recent Developments
  79. 4.14 AstraZeneca
  80. 4.14.1 AstraZeneca Company Information
  81. 4.14.2 AstraZeneca Business Overview
  82. 4.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 AstraZeneca C-MET & HGF Inhibitors Product Portfolio
  84. 4.14.5 AstraZeneca Recent Developments
  85. 4.15 Mirati Therapeutics
  86. 4.15.1 Mirati Therapeutics Company Information
  87. 4.15.2 Mirati Therapeutics Business Overview
  88. 4.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio
  90. 4.15.5 Mirati Therapeutics Recent Developments
  91. 4.16 Eli Lilly
  92. 4.16.1 Eli Lilly Company Information
  93. 4.16.2 Eli Lilly Business Overview
  94. 4.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Eli Lilly C-MET & HGF Inhibitors Product Portfolio
  96. 4.16.5 Eli Lilly Recent Developments
  97. 4.17 Johnson & Johnson
  98. 4.17.1 Johnson & Johnson Company Information
  99. 4.17.2 Johnson & Johnson Business Overview
  100. 4.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio
  102. 4.17.5 Johnson & Johnson Recent Developments
  103. 4.18 Eisai
  104. 4.18.1 Eisai Company Information
  105. 4.18.2 Eisai Business Overview
  106. 4.18.3 Eisai C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Eisai C-MET & HGF Inhibitors Product Portfolio
  108. 4.18.5 Eisai Recent Developments
  109. 4.19 Hutchison MediPharma
  110. 4.19.1 Hutchison MediPharma Company Information
  111. 4.19.2 Hutchison MediPharma Business Overview
  112. 4.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio
  114. 4.19.5 Hutchison MediPharma Recent Developments
  115. 4.20 Kringle Pharmaceuticals
  116. 4.20.1 Kringle Pharmaceuticals Company Information
  117. 4.20.2 Kringle Pharmaceuticals Business Overview
  118. 4.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  120. 4.20.5 Kringle Pharmaceuticals Recent Developments
5 Global C-MET & HGF Inhibitors Market Scenario by Region
  1. 5.1 Global C-MET & HGF Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global C-MET & HGF Inhibitors Sales by Region: 2021-2032
  3. 5.2.1 Global C-MET & HGF Inhibitors Sales by Region: 2021-2026
  4. 5.2.2 Global C-MET & HGF Inhibitors Sales by Region: 2027-2032
  5. 5.3 Global C-MET & HGF Inhibitors Revenue by Region: 2021-2032
  6. 5.3.1 Global C-MET & HGF Inhibitors Revenue by Region: 2021-2026
  7. 5.3.2 Global C-MET & HGF Inhibitors Revenue by Region: 2027-2032
  8. 5.4 North America C-MET & HGF Inhibitors Market Facts & Figures by Country
  9. 5.4.1 North America C-MET & HGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America C-MET & HGF Inhibitors Sales by Country (2021-2032)
  11. 5.4.3 North America C-MET & HGF Inhibitors Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe C-MET & HGF Inhibitors Market Facts & Figures by Country
  16. 5.5.1 Europe C-MET & HGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe C-MET & HGF Inhibitors Sales by Country (2021-2032)
  18. 5.5.3 Europe C-MET & HGF Inhibitors Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific C-MET & HGF Inhibitors Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific C-MET & HGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific C-MET & HGF Inhibitors Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific C-MET & HGF Inhibitors Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America C-MET & HGF Inhibitors Market Facts & Figures by Country
  41. 5.7.1 South America C-MET & HGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America C-MET & HGF Inhibitors Sales by Country (2021-2032)
  43. 5.7.3 South America C-MET & HGF Inhibitors Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa C-MET & HGF Inhibitors Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa C-MET & HGF Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa C-MET & HGF Inhibitors Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global C-MET & HGF Inhibitors Sales by Type (2021-2032)
  2. 6.1.1 Global C-MET & HGF Inhibitors Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2032)
  4. 6.2 Global C-MET & HGF Inhibitors Revenue by Type (2021-2032)
  5. 6.2.1 Global C-MET & HGF Inhibitors Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2032)
  7. 6.3 Global C-MET & HGF Inhibitors Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global C-MET & HGF Inhibitors Sales by Application (2021-2032)
  2. 7.1.1 Global C-MET & HGF Inhibitors Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2032)
  4. 7.2 Global C-MET & HGF Inhibitors Revenue by Application (2021-2032)
  5. 7.2.1 Global C-MET & HGF Inhibitors Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2032)
  7. 7.3 Global C-MET & HGF Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 C-MET & HGF Inhibitors Value Chain Analysis
  2. 8.1.1 C-MET & HGF Inhibitors Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 C-MET & HGF Inhibitors Production Mode & Process
  5. 8.2 C-MET & HGF Inhibitors Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 C-MET & HGF Inhibitors Distributors
  8. 8.2.3 C-MET & HGF Inhibitors Customers
9 Global C-MET & HGF Inhibitors Analyzing Market Dynamics
  1. 9.1 C-MET & HGF Inhibitors Industry Trends
  2. 9.2 C-MET & HGF Inhibitors Industry Drivers
  3. 9.3 C-MET & HGF Inhibitors Industry Opportunities and Challenges
  4. 9.4 C-MET & HGF Inhibitors Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst